Health science firm Revvity's preliminary Q4 revenue beats estimates

Overview

• Health science solutions provider's preliminary Q4 revenue grows 6%, beating analyst expectations

• Full year 2025 revenue expected to grow 4% to approximately $2.855 bln

• Company expects full year adjusted EPS to exceed upper-end of $4.90-$5.00 guidance

Outlook

• Company expects Q4 revenue of approximately $772 mln

• Revvity anticipates full-year revenue of approximately $2,855 mln

• Company expects full-year adjusted EPS to exceed the upper-end of the $4.90-$5.00 guidance provided in October

Result Drivers

• REPORTED AND ORGANIC REVENUE -Reported and organic revenue growth for the fourth quarter is expected to be approximately 6% and 4%, respectively, as compared to the same period a year ago

• FOREIGN EXCHANGE IMPACT - Revenue growth benefited from favorable foreign exchange rates, contributing 2% to reported growth

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Revvity Inc is $115.00, about 10.1% above its January 9 closing price of $104.43

• The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nBw2ZN64ya

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.